Drug
Menabcwy 2gen Low Dose Vaccine
Menabcwy 2gen Low Dose Vaccine: highest development phase Phase 1/2, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| MenABCWY-2Gen low dose vaccine NCT04886154 | Phase 1/2 | Infections, Meningococcal |
Latest
No recent events.
Follow Menabcwy 2gen Low Dose Vaccine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.